Studies on administration of thiamazole to breast-feeding mothers with Graves' disease

Setsuko Murase, Toru Sato, Hideya Kokubun, Toshimi Kimura, Masaaki Takahashi, Mitsuru Machida, Shigehiko Shimada, Takashi Nishikawa, Tsunehide Oyama, Mayumi Mochizuki, Yoshifumi Abe, Kunihiko Ito

研究成果: Article査読

抄録

We investigated the excretion of thiamazole, an antithyroid drug, in the milk of 6 mothers with Graves' disease. Thiamazole in serum or milk was determined by high performance liquid chromatography. The mothers had been taking thiamazole 5∼10 mg/day, before and after delivery. The drug concentration in serum was almost equal to that in milk; it reached maximum at about 2 hours after the previous administration and was considerably decreased at 12 hours. The babies were breast-fed at 12 hours or more after the previous administration, and the drug was not detected (below about 1 ng/ml) in the serum of any baby. Thyroid function test results were normal in all babies. These findings suggest that breast-feeding mothers with hyperthyroidism can continue thiamazole treatment, though further study is needed for assessment of safety, regarding the accumulation of the drug in the thyroid of babies.

本文言語English
ページ(範囲)775-782
ページ数8
ジャーナルJapanese Journal of Clinical Pharmacology and Therapeutics
30
6
DOI
出版ステータスPublished - 1999
外部発表はい

ASJC Scopus subject areas

  • 薬理学
  • 薬理学(医学)

フィンガープリント

「Studies on administration of thiamazole to breast-feeding mothers with Graves' disease」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル